Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study

Simple item page
dc.contributor.authorDoniną, Simona
dc.contributor.authorStrele, Ieva
dc.contributor.authorProboka, Guna
dc.contributor.authorAuziņš, Jurgis
dc.contributor.authorAlberts, Peteris
dc.contributor.authorJonsson, Björn
dc.contributor.authorVenskus, Dite
dc.contributor.authorMuceniece, Aina
dc.contributor.institutionInstitute of Microbiology and Virology
dc.contributor.institutionDepartment of Public Health and Epidemiology
dc.date.accessioned2021-07-27T12:05:01Z
dc.date.available2021-07-27T12:05:01Z
dc.date.issued2015-09-18
dc.descriptionPublisher Copyright: © 2015 Wolters Kluwer Health, Inc. All rights reserved.
dc.description.abstractAn oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004. The present retrospective study was carried out to determine the effectiveness of Rigvir in substage IB, IIA, IIB and IIC melanoma patients on time to progression and overall survival. White patients (N=79) who had undergone surgical excision of the primary melanoma tumour were included in this study. All patients were free from disease after surgery and classified into substages IB, IIA, IIB and IIC. Circulating levels of clinical chemistry parameters were recorded. Survival was analysed by Cox regression. Rigvir significantly (P<0.05) prolonged survival in substage IB-IIC melanoma patients following surgery compared with patients who were under observation (according to current guidelines). The hazard ratio for patients under observation versus treated with Rigvir was statistically significantly different: hazard ratio 6.27 for all, 4.39 for substage IIA-IIB-IIC and 6.57 for substage IIB-IIC patients. The follow-up period was not statistically different between both treatment groups. These results indicate that the patients treated with Rigvir had a 4.39-6.57-fold lower mortality than those under observation. In this study, there was no untoward side effect or discontinuation of Rigvir treatment. Safety assessment of adverse events graded according to NCI CTCAE did not show any value above grade 2 in Rigvir-treated patients. In conclusion, Rigvir significantly prolongs survival in early-stage melanoma patients without any side effect.en
dc.description.statusPeer reviewed
dc.format.extent6
dc.format.extent238413
dc.identifier.citationDoniną, S, Strele, I, Proboka, G, Auziņš, J, Alberts, P, Jonsson, B, Venskus, D & Muceniece, A 2015, 'Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study', Melanoma Research, vol. 25, no. 5, pp. 421-426. https://doi.org/10.1097/CMR.0000000000000180
dc.identifier.doi10.1097/CMR.0000000000000180
dc.identifier.issn0960-8931
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/5907
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84941795236&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofMelanoma Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectECHO-7 virus
dc.subjectimmunomodulator
dc.subjectimmunotherapy
dc.subjectmelanoma
dc.subjectoncolytic
dc.subjectvirotherapy
dc.subject3.2 Clinical medicine
dc.subject1.6 Biological sciences
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectOncology
dc.subjectDermatology
dc.subjectCancer Research
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAdapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective studyen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Adapted_ECHO_7_virus_Rigvir_immunotherapy.7.pdf
Size:
232.83 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure